Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies.
ESAT-6
HBHA
IGRA
tuberculous lymphadenopathy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 Mar 2023
08 Mar 2023
Historique:
received:
20
01
2023
revised:
10
02
2023
accepted:
06
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
The incidence of tuberculosis lymphadenopathy (TBLA) is increasing, and diagnostic procedures lack sensitivity and are often highly invasive. TBLA may be asymptomatic, and differential diagnosis with other adenopathies (ADPs) is difficult. We evaluated a blood-cell interferon-γ release assay (IGRA) with two different stage-specific mycobacterial antigens for the differential diagnosis of ADP suspected of mycobacterial origin. Twenty-one patients were included and divided into three groups: (1) cervical/axillar ADP ( An IGRA profile highly suggestive of active TB (higher IFN-γ response to ESAT-6 compared to HBHA) was found for 3/6 TBLA patients from group 1, and for all the TBLA patients from groups 2 and 3, whereas this profile was not noticed in patients with a final alternative diagnosis. These results highlight the potential value of this combined HBHA/ESAT-6 IGRA as a triage test for the differential diagnosis of ADP.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The incidence of tuberculosis lymphadenopathy (TBLA) is increasing, and diagnostic procedures lack sensitivity and are often highly invasive. TBLA may be asymptomatic, and differential diagnosis with other adenopathies (ADPs) is difficult. We evaluated a blood-cell interferon-γ release assay (IGRA) with two different stage-specific mycobacterial antigens for the differential diagnosis of ADP suspected of mycobacterial origin.
METHODS
METHODS
Twenty-one patients were included and divided into three groups: (1) cervical/axillar ADP (
RESULTS
RESULTS
An IGRA profile highly suggestive of active TB (higher IFN-γ response to ESAT-6 compared to HBHA) was found for 3/6 TBLA patients from group 1, and for all the TBLA patients from groups 2 and 3, whereas this profile was not noticed in patients with a final alternative diagnosis.
CONCLUSION
CONCLUSIONS
These results highlight the potential value of this combined HBHA/ESAT-6 IGRA as a triage test for the differential diagnosis of ADP.
Identifiants
pubmed: 36983128
pii: jcm12062127
doi: 10.3390/jcm12062127
pmc: PMC10052338
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Vaccine Immunol. 2014 Mar;21(3):321-8
pubmed: 24391135
BMC Nephrol. 2020 Jun 4;21(1):214
pubmed: 32498706
Expert Rev Vaccines. 2015;14(12):1573-85
pubmed: 26517361
J Thorac Dis. 2015 Mar;7(3):439-48
pubmed: 25922723
Adv Med Sci. 2019 Sep;64(2):437-443
pubmed: 31586819
PLoS One. 2007 Oct 03;2(10):e926
pubmed: 17912342
Insights Imaging. 2022 Mar 7;13(1):39
pubmed: 35254534
Respir Med. 2016 Mar;112:10-7
pubmed: 26860219
J Immunol. 2020 Apr 1;204(7):1715-1723
pubmed: 32122997
J Clin Microbiol. 2022 May 18;60(5):e0244321
pubmed: 35430897
PLoS One. 2011 Mar 29;6(3):e18315
pubmed: 21479248
Eur Respir J. 2016 Dec;48(6):1751-1763
pubmed: 27836953
Clin Microbiol Infect. 2021 Sep;27(9):1347.e1-1347.e7
pubmed: 33352301
PLoS One. 2012;7(8):e43285
pubmed: 22912846